Skip to main content

Table 3 Summary of the differences in the application of immune checkpoint inhibitors against common tumors, according to FDA approval information

From: Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Condition Drug ORR (%) mPFS (months) mOS (months) Grade 3–5 AE (%) Approval time Key trials
Melanoma Ipilimumab 16.8 2.70 11.2 11 03/2011 NCT00324155
Ipilimumab + nivolumab 60 8.50 Not reached 62 10/2015 CheckMate-067
Pembrolizumab 37 5.00 >  24 <  10 09/2014 KeyNote-001
Nivolumab 32 4.70 17.3 9 12/2014 CheckMate-037
Atezolizumab 60 15.10 16.1 33.5 07/2020 IMspire150
NSCLC Nivolumab 20 3.50 9.2 7 03/2015 CheckMate-063; CheckMate-017
Ipilimumab + nivolumab 36 5.1 17.1 58 05/2020 CheckMate-227
Pembrolizumab 19.4 4.00 12.7 <  10 10/2015 KeyNote-001; KeyNote-010
Atezolizumab 17 2.70 12.6 11 10/2016 Poplar (NCT01903993)
Durvalumab 28.4 16.80 23.2 29.9 02/2018 NCT02125461
Cemiplimab 39 8.20 Not reached 28 02/2021 NCT03088540
RCC Nivolumab 25 4.60 25 19 11/2015 CheckMate-025
Ipilimumab + nivolumab 41.6 11.6 Not reached 65 04/2018 CheckMate-214
Pembrolizumab 59.3 15.10 Not reached 75.8 04/2019 KeyNote-426
Avelumab 51.4 13.80 11.6 71.2 05/2019 JAVELIN Renal 101
HCC Nivolumab 14.3 4.00 15 25 09/2017 CheckMate-040
Ipilimumab + nivolumab 33 8.3 17.5 37 03/2020 Checkmate-040
Pembrolizumab 17 4.9 12.9 26 11/2018 KeyNote-224
Atezolizumab 65 6.80 Not evaluated 56.5 05/2020 IMbrave150
SCLC Nivolumab 12 1.4 5.6 45 08/2018 CheckMate-032
Atezolizumab 60.2 5.20 12.3 37 03/2019 Impower133
Pembrolizumab 19 2.0 8.7 31 06/2019 KeyNote-158; KeyNote-028
Durvalumab 68 5.10 13 62 03/2020 CASPIAN (NCT03043872)
CRC Nivolumab 32 14.30 5.6 45 08/2017 CheckMate-142
Ipilimumab + nivolumab 55 12 Not evaluated 20 07/2018 CheckMate-8HW
Pembrolizumab 43.8 16.50 13.7 22 06/2020 KeyNote-177
  1. ORR overall rate response, mPFS median progression free survival, mOS median overall survival, AE adverse events, NSCLC non-small-cell lung cancer, RCC renal cell carcinoma, HCC hepatocellular carcinoma, SCLC small-cell lung cancer, CRC colorectal cancer